Q3 2025 Earnings Estimate for Teva Pharmaceutical Industries Limited (NYSE:TEVA) Issued By Zacks Research

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities research analysts at Zacks Research upped their Q3 2025 EPS estimates for shares of Teva Pharmaceutical Industries in a research report issued on Wednesday, May 1st. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.62 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2025 earnings at $0.78 EPS and FY2025 earnings at $2.42 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The firm had revenue of $4.46 billion for the quarter, compared to analysts’ expectations of $3.97 billion.

A number of other brokerages have also weighed in on TEVA. The Goldman Sachs Group lifted their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their price target for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $12.00 to $19.00 in a report on Monday, February 12th. Finally, Barclays raised their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $13.98 on Friday. The business’s 50 day moving average price is $13.61 and its 200-day moving average price is $11.59. Teva Pharmaceutical Industries has a fifty-two week low of $7.09 and a fifty-two week high of $14.47. The company has a market cap of $15.67 billion, a P/E ratio of -29.74, a P/E/G ratio of 1.69 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02.

Insiders Place Their Bets

In related news, VP Eric Drape sold 173,261 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $13.05, for a total value of $2,261,056.05. Following the sale, the vice president now owns 1 shares in the company, valued at $13.05. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the transaction, the vice president now directly owns 1 shares in the company, valued at $13.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now directly owns 382,590 shares in the company, valued at $5,172,616.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 358,972 shares of company stock valued at $4,739,820. 0.55% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its position in Teva Pharmaceutical Industries by 705.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock worth $6,051,000 after purchasing an additional 507,568 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $3,000,000. SG Americas Securities LLC grew its stake in Teva Pharmaceutical Industries by 31.7% in the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after acquiring an additional 131,043 shares during the period. Wellington Management Group LLP increased its holdings in Teva Pharmaceutical Industries by 42.2% in the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock worth $3,515,000 after acquiring an additional 102,261 shares in the last quarter. Finally, Gateway Investment Advisers LLC raised its position in Teva Pharmaceutical Industries by 28.6% during the fourth quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock worth $437,000 after acquiring an additional 9,312 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.